(24/7 MARKET NEWS) – Ocean Biomedical, Inc. (NASDAQ: OCEA) repeated, this morning, that it’s celebrating the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%.
Ocean Biomedical is at $5.32, up $0.60 (+10.60%), on trading volume of 460 thousand premarket shares.
Its 52-week trading range is $3.06 to $14.22. It really started trading earlier this month, so, if it can keep the strong volume going, it doesn’t have much resistance to the $10 level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.